Skip to main content
BIIB logo

BIIB · Biogen Inc. · Webcasts, Transcripts & Audio

Track BIIB — free
Market Cap
$37.46B
Shares
147.82M
Volume · Nov 13 1.03M Avg daily vol (3M) 1.07M

Biogen Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Biogen Inc. (BIIB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-17
Biogen Inc. (BIIB) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-10-28
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
Confident tone Lupus development and commercialization AMR and MBI market development Growth product launches
Revenue
$2.80B
▲ 10.6% YoY
Diluted EPS
$-0.14
▼ 104.4% YoY
Gross margin
73.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
Biogen Inc. (BIIB) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Biogen Inc. (BIIB) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-29
Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript
Confident tone Late-stage registrational pipeline BTK inhibitor (BIP-91) and competitive MS market Appellu acquisition integration
Revenue
$2.74B
▲ 3.4% YoY
Diluted EPS
$0.66
▼ 84.8% YoY
Gross margin
71.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-07-14
Biogen Inc. (BIIB) July 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-07-12
Biogen Inc. (BIIB) July 12, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-07-07
Biogen Inc. (BIIB) July 7, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-13
Biogen Inc. (BIIB) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-29
Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript
Confident tone Leqembi franchise and care pathway Pellas/Pelagos acquisition Growth product momentum
Revenue
$2.48B
▲ 1.9% YoY
Diluted EPS
$2.15
▲ 31.1% YoY
Gross margin
73.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-06
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Confident tone Pipeline and R&D progress Leqembi / Alzheimer's franchise Newer product launches (Skyclaris, XERZUVEY, SPINRAZA HD)
Revenue
$2.28B*
▼ 7.1% YoY
Gross margin
78.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-12
Biogen Inc. (BIIB) January 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-10-30
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
Confident tone Launch product momentum Late-stage pipeline and readouts Tau / BIIB080 readout and external data read-throughs
Revenue
$2.53B
▲ 2.8% YoY
Diluted EPS
$3.17
▲ 19.2% YoY
Gross margin
73.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Confident tone LEQEMBI / Alzheimer's franchise Pipeline progress and milestones Eisai partnership / Europe arbitration
Revenue
$2.65B
▲ 7.3% YoY
Diluted EPS
$4.33
▲ 8.2% YoY
Gross margin
77.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
Positive tone Pipeline and external innovation LEQEMBI launch and growth Alzheimer's prevention trials
Revenue
$2.43B
▲ 6.1% YoY
Diluted EPS
$1.64
▼ 39.3% YoY
Gross margin
74.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Positive tone LEQEMBI growth and Alzheimer's franchise New product launches offsetting MS decline Pipeline reprioritization and future readouts
Revenue
$2.45B*
▲ 2.9% YoY
Gross margin
76.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript
Positive tone ZURZUVAE launch SKYCLARYS global expansion LEQEMBI launch
Revenue
$2.47B
▼ 2.5% YoY
Diluted EPS
$2.66
Gross margin
74.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Confident tone LEQEMBI and Alzheimer's franchise Business development and M&A (HI-Bio) New product launches (SKYCLARYS, ZURZUVAE, Reata)
Revenue
$2.46B
▲ 0.4% YoY
Diluted EPS
$4.00
▼ 1.7% YoY
Gross margin
77.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript
Positive tone LEQEMBI launch and Alzheimer's market Quarterly financial performance SKYCLARYS launch and rare disease
Revenue
$2.29B
▼ 7% YoY
Diluted EPS
$2.70
▲ 1.1% YoY
Gross margin
76.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-13
Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript
Confident tone LEQEMBI (Alzheimer's disease franchise) SKYCLARYS launch and Friedreich's Ataxia International expansion (Japan, Europe, Latin America)
Revenue
$2.39B*
▼ 6.2% YoY
Gross margin
74.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
Revenue
$2.53B
▲ 0.9% YoY
Diluted EPS
$-0.47
▼ 106% YoY
Gross margin
73.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Biogen Inc. (BIIB) Q2 2023 Earnings Call Transcript
Revenue
$2.46B
▼ 5.1% YoY
Diluted EPS
$4.07
▼ 43.8% YoY
Gross margin
75.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-04-25
Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript
Revenue
$2.46B
▼ 2.7% YoY
Diluted EPS
$2.67
▲ 29.6% YoY
Gross margin
73.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-15
Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript
Revenue
$2.54B*
▼ 6.9% YoY
Gross margin
77.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-25
Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript
Revenue
$2.51B
▼ 9.7% YoY
Diluted EPS
$7.84
▲ 253.2% YoY
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-20
Biogen Inc. (BIIB) Q2 2022 Earnings Call Transcript
Revenue
$2.59B
▼ 6.7% YoY
Diluted EPS
$7.24
▲ 142.1% YoY
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Biogen Inc. (BIIB) Q1 2022 Earnings Call Transcript
Revenue
$2.53B
▼ 6% YoY
Diluted EPS
$2.06
▼ 23.4% YoY
Gross margin
70.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-03
Biogen Inc. (BIIB) Q4 2021 Earnings Call Transcript
Revenue
$2.73B*
▼ 4.2% YoY
Gross margin
75.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Biogen Inc. (BIIB) Q3 2021 Earnings Call Transcript
Revenue
$2.78B
▼ 17.7% YoY
Diluted EPS
$2.22
▼ 50.2% YoY
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Biogen Inc. (BIIB) Q2 2021 Earnings Call Transcript
Revenue
$2.77B
▼ 24.6% YoY
Diluted EPS
$2.99
▼ 68.8% YoY
Gross margin
83.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-22
Biogen Inc. (BIIB) Q1 2021 Earnings Call Transcript
Revenue
$2.69B
▼ 23.8% YoY
Diluted EPS
$2.69
▼ 66.7% YoY
Gross margin
82.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Biogen Inc. (BIIB) Q4 2020 Earnings Call Transcript
Revenue
$2.85B
▼ 22.3% YoY
Diluted EPS
$2.32
▼ 71.3% YoY
Gross margin
82.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Biogen Inc. (BIIB) Q3 2020 Earnings Call Transcript
Revenue
$3.38B
▼ 6.2% YoY
Diluted EPS
$4.46
▼ 46.8% YoY
Gross margin
86.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-22
Biogen Inc. (BIIB) Q2 2020 Earnings Call Transcript
Revenue
$3.68B
▲ 1.8% YoY
Diluted EPS
$9.59
▲ 22.2% YoY
Gross margin
88.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-22
Biogen Inc. (BIIB) Q1 2020 Earnings Call Transcript
Revenue
$3.53B
▲ 1.3% YoY
Diluted EPS
$8.08
▲ 13% YoY
Gross margin
87.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-30
Biogen Inc. (BIIB) Q4 2019 Earnings Call
Revenue
$3.67B
▲ 4.1% YoY
Diluted EPS
$8.08
▲ 70.8% YoY
Gross margin
87.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–36 of 36 webcasts
Key facts CIK 875045 CUSIP 09062X103 13F (30d) 826 filings 761 filers Visit website Investor relations